The U.S. microarray market size was estimated at USD 2.65 billion in 2024 and is projected to grow at a CAGR of 5.7% from 2025 to 2033. The market is driven by the surging demand for personalized medicine, especially in precision oncology and pharmacogenomics. With rising investments from the NIH, universities, and biotech firms, microarrays are invaluable for identifying biomarkers, profiling gene expression, and tailoring therapeutic regimens-ultimately improving patient outcomes. In addition, the escalating prevalence of cancer and chronic diseases further enhances reliance on high-throughput genomic tools like microarrays for early detection and drug discovery.
Recent advancements in cancer research have significantly leveraged microarray instruments and reagents to enhance diagnostic accuracy and molecular profiling. Microarray platforms are increasingly used for gene expression profiling, allowing researchers to identify cancer-specific biomarkers, predict prognosis, and guide targeted therapies. In the U.S., companies such as Thermo Fisher Scientific, Agilent Technologies, and Illumina have introduced updated reagent kits optimized for high-throughput assays and low input RNA/DNA samples-critical for analyzing tumor biopsies. For instance, Thermo Fisher's GeneChip reagents support whole-transcriptome analysis in oncology research, while Agilent’s SureTag DNA labeling kits enable robust hybridization for comparative genomic hybridization (CGH) in cancer cytogenetics. Illumina’s Infinium assay kits, widely compatible with the iScan system, allow for simultaneous interrogation of methylation and SNP profiles, aiding in epigenetic cancer studies.
Growing investment and innovation in U.S.-based microarray technologies are poised to accelerate market growth, particularly in next-generation applications such as intradermal patch delivery. In March 2023, Vaxess Technologies, a Massachusetts-based biotech firm, secured an additional USD 9 million in funding to advance its MIMIX sustained-release intradermal microarray patch platform. This novel platform aims to revolutionize vaccine and therapeutic delivery by enabling self-administered, extended-release dosing through a skin patch. The funding, led by prominent U.S. investors such as RA Capital Management and The Engine (MIT’s venture fund), will support ongoing clinical trials for influenza and COVID-19 vaccines and broaden the platform’s applications into oncology, autoimmune diseases, and metabolic disorders.
Beyond healthcare, microarray technologies are gaining momentum in U.S. agriculture and environmental science. In precision farming, microarrays are used to decode plant genomes and identify traits that enhance resistance to pests and climate stressors, which are addressing U.S. food security challenges. Additionally, environmental agencies and academic institutions are increasingly using microarray-based toxicogenomic assays to evaluate the impact of pollutants on gene expression in local ecosystems. This multifaceted applicability-from clinical research to sustainability continues to expand the role of microarray instruments and reagents in driving innovation across sectors in the United States.
This product will be delivered within 1-3 business days.
Recent advancements in cancer research have significantly leveraged microarray instruments and reagents to enhance diagnostic accuracy and molecular profiling. Microarray platforms are increasingly used for gene expression profiling, allowing researchers to identify cancer-specific biomarkers, predict prognosis, and guide targeted therapies. In the U.S., companies such as Thermo Fisher Scientific, Agilent Technologies, and Illumina have introduced updated reagent kits optimized for high-throughput assays and low input RNA/DNA samples-critical for analyzing tumor biopsies. For instance, Thermo Fisher's GeneChip reagents support whole-transcriptome analysis in oncology research, while Agilent’s SureTag DNA labeling kits enable robust hybridization for comparative genomic hybridization (CGH) in cancer cytogenetics. Illumina’s Infinium assay kits, widely compatible with the iScan system, allow for simultaneous interrogation of methylation and SNP profiles, aiding in epigenetic cancer studies.
Growing investment and innovation in U.S.-based microarray technologies are poised to accelerate market growth, particularly in next-generation applications such as intradermal patch delivery. In March 2023, Vaxess Technologies, a Massachusetts-based biotech firm, secured an additional USD 9 million in funding to advance its MIMIX sustained-release intradermal microarray patch platform. This novel platform aims to revolutionize vaccine and therapeutic delivery by enabling self-administered, extended-release dosing through a skin patch. The funding, led by prominent U.S. investors such as RA Capital Management and The Engine (MIT’s venture fund), will support ongoing clinical trials for influenza and COVID-19 vaccines and broaden the platform’s applications into oncology, autoimmune diseases, and metabolic disorders.
Beyond healthcare, microarray technologies are gaining momentum in U.S. agriculture and environmental science. In precision farming, microarrays are used to decode plant genomes and identify traits that enhance resistance to pests and climate stressors, which are addressing U.S. food security challenges. Additionally, environmental agencies and academic institutions are increasingly using microarray-based toxicogenomic assays to evaluate the impact of pollutants on gene expression in local ecosystems. This multifaceted applicability-from clinical research to sustainability continues to expand the role of microarray instruments and reagents in driving innovation across sectors in the United States.
U.S. Microarray Market Report Segmentation
This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, the analyst has segmented the U.S. microarray market report based on products and services, type, application, and end use.Product and Services Outlook (Revenue, USD Million, 2021 - 2033)
- Consumables
- Software and Services
- Instruments
Type Outlook (Revenue, USD Million, 2021 - 2033)
- DNA Microarrays
- Protein Microarrays
- Others
Application Outlook (Revenue, USD Million, 2021 - 2033)
- Research Applications
- Drug Discovery
- Disease Diagnostics
- Others
End Use Outlook (Revenue, USD Million, 2021 - 2033)
- Research & Academic Institutes
- Pharmaceutical & Biotechnology Companies
- Diagnostic Laboratories
- Others
Why should you buy this report?
- Comprehensive Market Analysis: Gain detailed insights into the global market across major regions and segments.
- Competitive Landscape: Explore the market presence of key players worldwide.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the global market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
This report addresses:
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segment and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listing for you to stay ahead of the curve
- COVID-19's impact and how to sustain in these fast-evolving markets
This product will be delivered within 1-3 business days.
Table of Contents
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. U.S. Microarray Market Variables, Trends & Scope
Chapter 4. U.S. Microarray Market: Product and Services Estimates & Trend Analysis
Chapter 5. U.S. Microarray Market: Type Estimates & Trend Analysis
Chapter 6. U.S. Microarray Market: Application Estimates & Trend Analysis
Chapter 7. U.S. Microarray Market: End use Estimates & Trend Analysis
Chapter 8. Competitive Landscape
List of Tables
List of Figures
Companies Mentioned
- Thermo Fisher Scientific Inc (Applied Biosystems)
- Agilent Technologies, Inc
- Illumina, Inc
- PerkinElmer Inc.
- Merck KGaA
- Schott (Applied Microarrays)
- Danaher Corporation
- Arrayit Corporation (ARYC)
- Bio-Rad Laboratories, Inc
- Microarrays Inc
